Literature DB >> 21978426

Optimal combination of immunohistochemical markers for subclassification of non-small cell lung carcinomas: A tissue microarray study of poorly differentiated areas.

Songmi Noh1, Hyosup Shim.   

Abstract

BACKGROUND: Recently, studies have been reported on the optimal immunohistochemical markers for subclassification of non-small cell lung carcinoma (NSCLC). The main pitfall in subclassification of NSCLC is small specimen with poorly differentiated area. In this study, we added newly proposed markers (e.g., napsin A, SOX2) to conventional markers (p63, TTF-1, CK5/6, and CK7) and evaluated optimal combination for subtyping of NSCLC, primarily focusing on the poorly differentiated area.
METHODS: Eighty two resected NSCLCs with poorly differentiated areas were classified based on histologic findings. After histologic review, only poorly differentiated areas were selected and tissue microarrays were constructed to simulate small biopsy conditions. A total of 36 adenocarcinomas (ADCs), 38 squamous cell carcinomas (SQCCs), and 8 large cell carcinomas were included. All specimens were stained with TTF-1, napsin A, CK7, p63, CK5/6, and SOX2.
RESULTS: With respect to ADC, TTF-1 was positive in 19 of 36 cases (53%) and napsin A was in 25 of 36 (69%). Both markers were specific for ADC (100% and 98%, respectively). With TTF-1 and napsin A in combination, sensitivity increased to 75%. CK7 was sensitive (92%) but not specific marker (76%) for ADC. With respect to SQCC, p63 was positive in 35 of 38 cases (92%) and CK5/6 was in 23 (61%). Both markers were specific for SQCC (both 93%). With p63 and CK5/6 in combination, sensitivity increased slightly to 95%, but specificity was lower at 91%. SOX2 was specific (100%) but not sensitive marker (53%) for SQCC. Combinations did not substantially increase the diagnostic performance.
CONCLUSION: A simple panel of napsin A, TTF-1, and p63 can be sufficient to reliably subclassify poorly differentiated areas of NSCLC. Copyright Â
© 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21978426     DOI: 10.1016/j.lungcan.2011.09.008

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  16 in total

Review 1.  Advances in lung adenocarcinoma classification: a summary of the new international multidisciplinary classification system (IASLC/ATS/ERS).

Authors:  Elizabeth R Tang; Andrew M Schreiner; Bradley B Pua
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

2.  Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for Chinese patients with squamous cell carcinoma of lung harboring EGFR mutation.

Authors:  Wenfeng Fang; Jianwei Zhang; Wenhua Liang; Yan Huang; Yue Yan; Xuan Wu; Zhihuang Hu; Yuxiang Ma; Hongyun Zhao; Yuanyuan Zhao; Yunpeng Yang; Cong Xue; Jing Zhang; Li Zhang
Journal:  J Thorac Dis       Date:  2013-10       Impact factor: 2.895

3.  MiR-205 and MiR-375 microRNA assays to distinguish squamous cell carcinoma from adenocarcinoma in lung cancer biopsies.

Authors:  Santosh Patnaik; Reema Mallick; Eric Kannisto; Rohit Sharma; Wiam Bshara; Sai Yendamuri; Samjot Singh Dhillon
Journal:  J Thorac Oncol       Date:  2015-03       Impact factor: 15.609

4.  Guideline Recommendations for EGFR Mutation Testing in Lung Cancer: Proposal of the Korean Cardiopulmonary Pathology Study Group.

Authors:  Hyo Sup Shim; Jin-Haeng Chung; Lucia Kim; Sunhee Chang; Wan-Seop Kim; Geon Kook Lee; Soon-Hee Jung; Se Jin Jang
Journal:  Korean J Pathol       Date:  2013-04-24

5.  Simultaneous multi-antibody staining in non-small cell lung cancer strengthens diagnostic accuracy especially in small tissue samples.

Authors:  Gian Kayser; Agnes Csanadi; Claudia Otto; Till Plönes; Nicola Bittermann; Justyna Rawluk; Bernward Passlick; Martin Werner
Journal:  PLoS One       Date:  2013-02-13       Impact factor: 3.240

6.  FAM83B is a novel biomarker for diagnosis and prognosis of lung squamous cell carcinoma.

Authors:  Naoyuki Okabe; Junji Ezaki; Takumi Yamaura; Satoshi Muto; Jun Osugi; Hirosumi Tamura; Jun-Ichi Imai; Emi Ito; Yuka Yanagisawa; Reiko Honma; Mitsukazu Gotoh; Shinya Watanabe; Satoshi Waguri; Hiroyuki Suzuki
Journal:  Int J Oncol       Date:  2015-01-07       Impact factor: 5.650

7.  The high diagnostic accuracy of combined test of thyroid transcription factor 1 and Napsin A to distinguish between lung adenocarcinoma and squamous cell carcinoma: a meta-analysis.

Authors:  Li Li; Xiaorong Li; Jieyun Yin; Xia Song; Xiaochen Chen; Jiane Feng; Hongyu Gao; Li Liu; Sheng Wei
Journal:  PLoS One       Date:  2014-07-08       Impact factor: 3.240

Review 8.  An Algorithmic Immunohistochemical Approach to Define Tumor Type and Assign Site of Origin.

Authors:  Andrew M Bellizzi
Journal:  Adv Anat Pathol       Date:  2020-05       Impact factor: 4.571

Review 9.  Tissue slide-based microRNA characterization of tumors: how detailed could diagnosis become for cancer medicine?

Authors:  Lorenzo F Sempere
Journal:  Expert Rev Mol Diagn       Date:  2014-08-04       Impact factor: 5.225

10.  Screening of ROS1 rearrangements in lung adenocarcinoma by immunohistochemistry and comparison with ALK rearrangements.

Authors:  Yoon Jin Cha; Jae Seok Lee; Hye Ryun Kim; Sun Min Lim; Byoung Chul Cho; Chang Young Lee; Hyo Sup Shim
Journal:  PLoS One       Date:  2014-07-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.